Skip to main content

CHICAGO - More bad news for CytRx (CYTR) at the American Society of Clinical Oncology annual meeting.

Results from the phase III study of CytRx's aldoxorubicin in front-line sarcoma patients were presented on Friday. The company had previously acknowledged aldoxorubicin's failure to significantly prolong progression-free survival, the study's primary endpoint. 

But what about survival? Maybe aldoxorubicin is helping sarcoma patients live longer? 

No, it is not. 

Image placeholder title

Read More Trending Articles:

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.